Coloplast: Healthcare switching costs + reimbursement moat at 23% margin of safety

Current Price

kr421.30

Unrealized P&L

-1.0%

Entry Zone

kr425.70

Target

kr550.00

+29.2% upside

Stop Loss

kr350.00

Catalyst

Trading within entry zone — half position

Time Horizon

52 weeks

Investment Thesis

Coloplast dominates intimate healthcare (ostomy, continence, wound care) with a quality score of 8/10. Clinical switching costs are exceptionally high — patients and clinicians rarely change products once established. Reimbursement barriers and scale advantages reinforce the moat. Fair value base case: 550 DKK (bear: 380, bull: 750). Entry zone: 370-430 DKK. Initiated half position at 425.70 DKK, looking to add on weakness toward 370 DKK.